Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$76.64
+0.6%
$80.76
$67.37
$122.67
$13.23B1.311.58 million shs386,471 shs
BXP, Inc. stock logo
BXP
BXP
$71.02
-1.0%
$72.06
$54.22
$90.11
$11.24B1.221.64 million shs544,653 shs
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$40.63
+0.2%
$41.31
$27.07
$45.03
$4.80B1.241.50 million shs876,688 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.87
+0.5%
$25.90
$23.15
$57.69
$10.89B2.0110.80 million shs3.14 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
+1.61%+1.46%-10.83%-3.35%-37.05%
BXP, Inc. stock logo
BXP
BXP
+1.68%-1.97%-8.03%+3.61%-17.19%
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
+0.10%-2.00%-7.04%+10.36%+1.13%
Moderna, Inc. stock logo
MRNA
Moderna
+5.60%-0.72%+16.08%-13.91%-51.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$76.64
+0.6%
$80.76
$67.37
$122.67
$13.23B1.311.58 million shs386,471 shs
BXP, Inc. stock logo
BXP
BXP
$71.02
-1.0%
$72.06
$54.22
$90.11
$11.24B1.221.64 million shs544,653 shs
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$40.63
+0.2%
$41.31
$27.07
$45.03
$4.80B1.241.50 million shs876,688 shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.87
+0.5%
$25.90
$23.15
$57.69
$10.89B2.0110.80 million shs3.14 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
+1.61%+1.46%-10.83%-3.35%-37.05%
BXP, Inc. stock logo
BXP
BXP
+1.68%-1.97%-8.03%+3.61%-17.19%
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
+0.10%-2.00%-7.04%+10.36%+1.13%
Moderna, Inc. stock logo
MRNA
Moderna
+5.60%-0.72%+16.08%-13.91%-51.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
2.08
Hold$95.8725.10% Upside
BXP, Inc. stock logo
BXP
BXP
2.32
Hold$78.9511.16% Upside
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
2.08
Hold$40.830.51% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$40.9346.87% Upside

Current Analyst Ratings Breakdown

Latest ARE, MRNA, BXP, and KRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/13/2025
BXP, Inc. stock logo
BXP
BXP
New Street Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$85.00
10/13/2025
BXP, Inc. stock logo
BXP
BXP
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$79.00 ➝ $84.00
10/13/2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$33.00 ➝ $45.00
10/13/2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
New Street Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$45.00
10/13/2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$88.00 ➝ $79.00
10/13/2025
BXP, Inc. stock logo
BXP
BXP
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$79.00 ➝ $84.00
10/13/2025
BXP, Inc. stock logo
BXP
BXP
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$85.00
10/10/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$31.00 ➝ $32.00
10/8/2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
BXP, Inc. stock logo
BXP
BXP
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$3.02B4.39$8.60 per share8.91$129.29 per share0.59
BXP, Inc. stock logo
BXP
BXP
$3.41B3.30$7.70 per share9.22$50.21 per share1.41
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$1.14B4.23$4.84 per share8.39$47.51 per share0.86
Moderna, Inc. stock logo
MRNA
Moderna
$3.06B3.56N/AN/A$28.33 per share0.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$322.95M-$0.13N/A7.976.31-0.33%-0.05%-0.03%10/27/2025 (Estimated)
BXP, Inc. stock logo
BXP
BXP
$14.27M$0.032,366.229.777.380.11%3.89%1.20%10/28/2025 (Confirmed)
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$210.97M$1.8422.069.79N/A19.29%3.92%1.99%10/27/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)

Latest ARE, MRNA, BXP, and KRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
10/28/2025Q3 2025
BXP, Inc. stock logo
BXP
BXP
$1.73N/AN/AN/A$860.88 millionN/A
10/27/2025Q3 2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$2.31N/AN/AN/A$752.90 millionN/A
10/27/2025Q3 2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$1.00N/AN/AN/A$271.24 millionN/A
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
7/29/2025Q2 2025
BXP, Inc. stock logo
BXP
BXP
$1.67$1.71+$0.04$1.71$845.09 million$868.46 million
7/28/2025Q2 2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$1.01$1.13+$0.12$1.13$268.84 million$289.89 million
7/21/2025Q2 2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$2.29$2.33+$0.04$2.33$748.02 million$737.28 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
$5.286.89%N/AN/A 15 Years
BXP, Inc. stock logo
BXP
BXP
$2.803.94%N/A9,333.33%N/A
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
$2.165.32%N/A117.39%N/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest ARE, MRNA, BXP, and KRC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/9/2025
BXP, Inc. stock logo
BXP
BXP
quarterly$0.703.76%9/30/20259/30/202510/31/2025
9/2/2025
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
quarterly$1.326.34%9/30/20259/30/202510/15/2025
9/16/2025
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
quarterly$0.545.11%9/30/20259/30/202510/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
0.61
0.23
0.23
BXP, Inc. stock logo
BXP
BXP
2.06
3.76
3.76
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
0.82
2.35
2.35
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77

Institutional Ownership

CompanyInstitutional Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
96.54%
BXP, Inc. stock logo
BXP
BXP
98.72%
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
94.22%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
1.08%
BXP, Inc. stock logo
BXP
BXP
1.49%
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
1.57%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alexandria Real Estate Equities, Inc. stock logo
ARE
Alexandria Real Estate Equities
590172.96 million171.09 millionOptionable
BXP, Inc. stock logo
BXP
BXP
780158.38 million156.02 millionOptionable
Kilroy Realty Corporation stock logo
KRC
Kilroy Realty
260118.29 million116.44 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable

Recent News About These Companies

Moderna posts melanoma data behind decision to say 'I do' to IDO
Moderna (MRNA) Stock Trades Up, Here Is Why
Moderna Claims Early Victory for Cancer Antigen in Melanoma
Moderna (NASDAQ:MRNA) Price Target Raised to $32.00
4 Analysts Assess Moderna: What You Need To Know

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alexandria Real Estate Equities stock logo

Alexandria Real Estate Equities NYSE:ARE

$76.64 +0.43 (+0.56%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

BXP stock logo

BXP NYSE:BXP

$71.02 -0.71 (-0.99%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.

Kilroy Realty stock logo

Kilroy Realty NYSE:KRC

$40.63 +0.09 (+0.21%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kilroy Realty Corporation (NYSE: KRC, the company, Kilroy) is a leading U.S. landlord and developer, with operations in San Diego, Greater Los Angeles, the San Francisco Bay Area, Greater Seattle and Austin. The company has earned global recognition for sustainability, building operations, innovation and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the company's approach to modern business environments helps drive creativity and productivity for some of the world's leading technology, entertainment, life science and business services companies. The company is a publicly traded real estate investment trust (REIT) and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring and managing office, life science and mixed-use projects. As of December 31, 2023, Kilroy's stabilized portfolio totaled approximately 17.0 million square feet of primarily office and life science space that was 85.0% occupied and 86.4% leased. The company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 92.5%. In addition, the company had two in-process life science redevelopment projects totaling approximately 100,000 square feet with total estimated redevelopment costs of $80.0 million and one approximately 875,000 square foot in-process development project with a total estimated investment of $1.0 billion.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.87 +0.15 (+0.54%)
As of 11:58 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.